One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
Price : 100$- Special Price : 50$
Prompting Introspection.
doi : 10.1161/CIRCULATIONAHA.125.074009
Volume 151(19) pgs. 1375-1432,e986-e1001 May 13, 2025
Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCM.
Cell Type-Level Epigenetics at the Frontier of Atherosclerosis Research.
Targeting uPARAP Modifies Lymphatic Vessel Architecture and Attenuates Lymphedema.
The Association Between Tirzepatide Versus Insulin Glargine and NT-proBNP Levels in People With Type 2 Diabetes With or at Elevated Risk for Cardiovascular Disease: Post hoc Analyses of SURPASS 4.
Letter by Zhang et al Regarding Article, "Excess Mortality and Loss of Life Expectancy After Myocardial Infarction: A Registry-Based Matched Cohort Study".
Response by Reitan et al to Letter Regarding Article, "Excess Mortality and Loss of Life Expectancy After Myocardial Infarction: A Registry-Based Matched Cohort Study".
Sedentary Behavior and Light-Intensity Physical Activity During Pregnancy and Cardiovascular Health: A Science Advisory From the American Heart Association.
Correction to: Sedentary Behavior and Light-intensity Physical Activity During Pregnancy and Cardiovascular Health: A Science Advisory From the American Heart Association.
Correction to: Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results from VALOR-HCM.
